Publication Date:
2021
abstract:
Pathophysiology and effects of endogenous glucocorticoid (GC) excess on skeletal endpoints as well as awareness and management of bone fragility are reviewed. Cushing's syndrome (CS) increase the risk of fracture affecting prevalently bone quality. Bone antiresorptive agents (SERMs, bisphosphonates and denosumab) as well as teriparatide increase bone mineral density and in some instances reduce fracture risk. Awareness and management of bone health in CS can be improved.(c) 2021 Elsevier Ltd. All rights reserved.
Iris type:
1.1.3. Articolo in Rivista - Editorial, Comment, Reply
Keywords:
adrenal incidentaloma; bone mineral density; bone quality; cushing disease; fractures; glucocorticoids
List of contributors:
Frara, Stefano; Allora, Agnese; di Filippo, Luigi; Formenti, Anna Maria; Loli, Paola; Polizzi, Elisabetta; Tradati, Daniele; Ulivieri, Fabio Massimo; Giustina, Andrea
Published in: